Blood test to predict cancer coming back after liver transplant
Part of Cancer, Digestive system clinical trials.
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to take part and sign the informed consent form
- You have been diagnosed with hepatocellular carcinoma (primary liver cancer)
- You are age 18 or older
- You are able to attend scheduled study visits and blood tests
- You are eligible for a liver transplant or currently on the transplant waiting list
- You have met with the Gastroenterology and Hepatology department
- You do not have other types of liver tumors (such as bile duct cancer or liver metastases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study looks at how well the HepatoPredict tool predicts outcomes for people with liver cancer who had a liver transplant or surgery to remove the tumor. The researchers are checking if the tool was accurate by reviewing data from at least 5 years after the procedure.
This trial tests whether a blood test that tracks circulating tumor cells (CTCs) can help doctors detect early signs of liver cancer returning after surgery. It aims to give patients and their doctors a better way to monitor for recurrence.
This study looks for a new blood marker that may predict how well liver cancer will respond to radiation and what outcomes to expect. It’s for people with hepatitis B–related liver cancer who can safely receive radiation to the liver tumor.
This trial is testing if a blood test can find liver cancer early. It may help people who are newly diagnosed or suspected to have liver cancer and have not started treatment yet.
This study looks at two blood markers (AFP and PIVKA-II) to see if they can help predict outcomes for people getting a liver transplant for liver cancer. It aims to find better ways to guide care after transplant.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.